White H S, Johnson M, Wolf H H, Kupferberg H J
Department of Pharmacology and Toxicology, College of Pharmacy University of Utah, Salt Lake City, USA.
Ital J Neurol Sci. 1995 Feb-Mar;16(1-2):73-7. doi: 10.1007/BF02229077.
A number of widely different animal seizure models have been employed in the search for new and novel anticonvulsant drugs useful for the treatment of human epilepsy. At present, no single laboratory test will, in itself, establish the presence or absence of anticonvulsant activity or fully predict the clinical potential of a test substance. Of the many available animal models, the maximal electroshock (MES) and subcutaneous pentylenetetrazol (scPTZ) tests still represent the most commonly employed models for the routine screening and identification of new anticonvulsant drugs. This chapter will briefly describe how these two tests are conducted, their limitations and how they have contributed in the past and to the present day anticonvulsant drug discovery process.
为了寻找可用于治疗人类癫痫的新型抗惊厥药物,人们采用了多种截然不同的动物癫痫模型。目前,没有任何一项单独的实验室测试能够仅凭自身确定一种物质是否具有抗惊厥活性,也无法完全预测其临床潜力。在众多现有的动物模型中,最大电休克(MES)和皮下注射戊四氮(scPTZ)测试仍是常规筛选和鉴定新型抗惊厥药物最常用的模型。本章将简要介绍这两种测试的操作方法、局限性,以及它们在过去和当今抗惊厥药物研发过程中所发挥的作用。